CTNI-46. A PHASE II TRIAL OF TUMOR TREATING FIELDS (TTFIELDS) CONCOMITANT WITH RADIOSURGERY FOR THE TREATMENT OF RECURRENT, BEVACIZUMAB-NAÏVE GLIOBLASTOMA

BACKGROUND: Almost all GBM patients experience recurrent disease, and median survival after recurrence is 6 months. A phase III trial conducted to test safety and efficacy of TTFields alone versus chemotherapy (including bevacizumab) in recurrent GBM showed improved PFS at six months and one-year su...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Harat, Maciej, Blok, Maciej, Adamczak-Sobczak, Magda, Szymanski, Pawel, Miechowicz, Iza, Malkowski, Bogdan
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2020
Schlagworte:
Clinical Trials: Non-Immunologic
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650494/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.212
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge